Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depression
- 31 October 1975
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 33 (2), 371-382
- https://doi.org/10.1016/0014-2999(75)90182-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Myocardial Depressant Effect of Beta-Receptor Blocking AgentsCirculation Research, 1974
- ??-Adrenergic Receptor Blocking Drugs in Angina PectorisDrugs, 1974
- Beta adrenergic blockade in hypertension: Practical and theoretical implications of long-term hemodynamic variationsThe American Journal of Cardiology, 1972
- Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise.Heart, 1971
- Pharmacological Testing Methods for Drugs Acting on the Peripheral Nervous SystemJournal of Pharmaceutical Sciences, 1970
- FREE NORADRENALINE AND ADRENALINE EXCRETION IN RELATION TO THE DEVELOPMENT OF CARDIAC ARRHYTHMIAS AND HEART-FAILURE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1969
- EVALUATION OF THE CARDIAC EFFECTS OF SEVERAL BETA ADRENERGIC BLOCKING AGENTSAnnals of the New York Academy of Sciences, 1967
- Metabolism of Propranolol (‘Inderal’), a Potent, Specific β-Adrenergic Receptor Blocking AgentNature, 1967
- Propranolol in hypertensionThe American Journal of Cardiology, 1966
- A NEW ADRENERGICThe Lancet, 1964